Motivational Refinements for Facilitating Reinforcement Schedule Thinning
Rutgers, The State University of New Jersey · NCT05790668
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 3–17 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 30
- US sites recruiting
- 2
- Study start
- October 24, 2023
- Record last updated
- August 12, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Destructive behavior represents a comorbid condition of developmental disability for which risk increases with intellectual disability severity, communication deficits, and co-occurring autism spectrum disorder. Destructive behavior, such as self-injurious behavior and aggression, causes harm to the child and others and increases the risk for institutionalization, social isolation, physical restraint, medication overuse, and abuse. Clinicians have used functional analyses to identify the variables that reinforce destructive behavior and to develop effective, function-based treatments. Functional communication training (FCT) is an empirically supported, function-based treatment that decreases destructive behavior. Using FCT, the clinician teaches the child to use a functional communication response (FCR) to request the reinforcer maintaining destructive behavior, while placing destructive behavior on extinction. For example, if functional analysis results showed that attention reinforced destructive behavior, the clinician would provide attention when the child used the FCR ("Play with me, please") and would not provide attention for destructive behavior. Two limitations of FCT are that (a) schedules of reinforcement maintaining the FCR must often be thinned gradually to levels that are practical for caregivers to implement consistently in the home and in the community, and (b) this necessary process of reinforcement schedule thinning regularly causes destructive behavior to increase following initially effective treatment, a form of treatment relapse called resurgence. The current project aims to improve these limitations of FCT by (a) hastening the process of reinforcement schedule thinning by removing unnecessary schedule-thinning steps using the results of a progressive interval assessment and (b) mitigating the resurgence of destructive behavior by providing stimuli that highly compete with the reinforcer maintaining destructive behavior. The investigators will conduct a randomized clinical trial to evaluate the extent to which these two promising refinements to FCT improve the process of reinforcement schedule thinning, and an exploratory experiment will examine the interactive effects of these two approaches. This novel project has the potential to substantially improve standards of care guiding the treatment of severe destructive behavior and to improve the long-term outcomes for children and families afflicted by these debilitating behavior disorders.
Being studied: Traditional Schedule Thinning; PIA-Informed Schedule Thinning; PIA-Informed Schedule Thinning with Competing Stimuli
Conditions: Decreasing Destructive Behavior; Increasing Functional Communicative Behavior
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- boys and girls from ages 3 to 17
- destructive behavior that occurs at least 10 times a day, despite previous treatment
- destructive behavior reinforced by social consequences
- stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment
- on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free
- stable educational plan and placement with no anticipated changes during the child's treatment
Exclusion Criteria
- patients who do not meet the inclusion criteria
- patients currently receiving 15 or more hours per week of treatment for their destructive behavior
- Diagnostic and Statistical Manual-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism)
- a comorbid health condition or major mental disorder that would interfere with study participation
- occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on routine clinical-risk assessment
- patients requiring changes to protective supports for self-injury or drug treatment, but investigators will invite these patients to participate when protective supports and drug regimen are stable
Recruiting US locations
Douglass Developmental Disabilities Center
New Brunswick, NJ 08901
Site contact: Robert LaRue, Ph.D. · 8489324500 · larue@rutgers.edu
Rutgers University Center for Autism Research, Education, and Services
Somerset, NJ 08873
Site contact: Brian D Greer, Ph.D. · 8488008505 · brian.greer@rutgers.edu
Study contacts (from the official record)
- Brian D Greer, Ph.D. · 8488008505 · brian.greer@rutgers.edu
- Daniel R Mitteer, Ph.D. · 8488008506 · daniel.mitteer@rutgers.edu
Similar studies in New Jersey
All healthy volunteers studies in New Jersey →- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Fair Lawn, NJ + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Merck Sharp & Dohme LLC
- Location
- Marlton, NJ + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Jersey City, NJ + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants
Harmony Biosciences Management, Inc.
- Location
- Eatontown, NJ
- Eligibility basics
- Ages 18–55